Natevba® (vevasumab):
Precision targeting in XA+
non-Hodgkin’s lymphoma
Introducing Natevba®
- Natevba® is an innovative new treatment targeting X-antigen1
- Natevba® is indicated for the first-line treatment of X-antigen positive (XA+) non-Hodgkin’s lymphoma1
Natevba® is the only treatment to target X-antigen, a highly specific marker of malignant lymphocytes1
Watch the video below to see Natevba® in action.